Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Response to crizotinib in a patient with MET-mutant papillary renal cell cancer after progression on tivantinib.

European urology - 1 Feb 2015

Stein Mark N, Hirshfield Kim M, Zhong Hua, Singer Eric A, Ali Siraj M, Ganesan Shridar

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Renal Cell
Share to Crizotinib
Share to Drug Substitution
Share to Proto-Oncogene Proteins c-met

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pyrazoles

Share to Pyridines

Share to Pyrrolidinones

Share to Quinolines

Source

Open in PubMed Open full text

Identifiers

PMID: 25457019
DOI: 10.1016/j.eururo.2014.10.012
PMCID: PMC5500309

Genes

MET

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Response to crizotinib in a patient with MET-mutant papillary renal cell cancer after progression on tivantinib.PMID 25457019Read ↗

MET Mutation Associated with Responsiveness to Crizotinib.Semantic proximity Read ↗

Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation.Semantic proximity Read ↗

Incorporation of crizotinib into the NCCN guidelines.Semantic proximity Read ↗

Remarkable tumor response to crizotinib in a 14-year-old girl with ALK-positive non-small-cell lung cancer.Semantic proximity Read ↗

Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial.Semantic proximity Read ↗

Overcoming Acquired Resistance Mutation MET D1228N to Crizotinib With Cabozantinib in NSCLC With MET Exon 14 Skipping Mutation.Semantic proximity Read ↗

MET-Mutated NSCLC with Major Response to Crizotinib.Semantic proximity Read ↗

Exceptional Response to Pazopanib in a Patient with Urothelial Carcinoma Harboring FGFR3 Activating Mutation and Amplification.Semantic proximity Read ↗

Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms.Semantic proximity Read ↗

Clinical Response to Pazopanib in a Patient With KDR-Mutated Metastatic Basal Cell Carcinoma.Semantic proximity Read ↗

Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR-Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study.Semantic proximity Read ↗

Response to a novel multitargeted tyrosine kinase inhibitor pazopanib in metastatic Merkel cell carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.